GS
APLS

GWN Securities’s Apellis Pharmaceuticals APLS Stock Holding History

GWN Securities’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,190
Closed -$454K – 414
2025
Q1 		$454K Buy
+27,190
New +$751K 0.03% 486

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GWN Securities's APLS Position: Q2 2025 in Review

GWN Securities sold out of Apellis Pharmaceuticals (APLS) in Q2 2025, closing a stake of 27,190 shares — an estimated $454K sold.

GWN Securities first reported a position in APLS in Q1 2025 and held it in 1 quarter. The position peaked at $454K in Q1 2025. 247 funds tracked by Wall St. Rank hold APLS as of Q2 2025.

  • GWN Securities reported no remaining Apellis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • GWN Securities sold 27,190 Apellis Pharmaceuticals shares in Q2 2025, an estimated $454K.
  • GWN Securities first reported a position in Apellis Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • GWN Securities's Apellis Pharmaceuticals position peaked at $454K in Q1 2025.
  • 247 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2025.

Based on GWN Securities's 13F filing for Q2 2025, filed 1 Aug 2025.